BTEK.L vs. SGLN.L
BTEK.L (iShares Nasdaq US Biotechnology UCITS ETF) and SGLN.L (iShares Physical Gold ETC) are both exchange-traded funds - BTEK.L is a Health & Biotech Equities fund tracking the NASDAQ Biotechnology TR USD, while SGLN.L is a Gold fund tracking the LBMA Gold Price. Both are passively managed. Over the past 5 years, BTEK.L returned 5.85%/yr vs 20.12%/yr for SGLN.L. At a 0.07 correlation, their price movements are largely independent. BTEK.L charges 0.35%/yr vs 0.12%/yr for SGLN.L.
Performance
BTEK.L vs. SGLN.L - Performance Comparison
Loading charts...
Different Trading Currencies
BTEK.L is traded in GBP, while SGLN.L is traded in GBp. To make them comparable, the SGLN.L values have been converted to GBP using the latest available exchange rates.
Returns By Period
In the year-to-date period, BTEK.L achieves a 4.86% return, which is significantly higher than SGLN.L's 3.89% return.
BTEK.L
- 1D
- 3.56%
- 1M
- 2.25%
- YTD
- 4.86%
- 6M
- 2.70%
- 1Y
- 43.15%
- 3Y*
- 10.19%
- 5Y*
- 5.85%
- 10Y*
- —
SGLN.L
- 1D
- 0.70%
- 1M
- -1.36%
- YTD
- 3.89%
- 6M
- 5.42%
- 1Y
- 33.75%
- 3Y*
- 28.17%
- 5Y*
- 20.12%
- 10Y*
- 14.27%
BTEK.L vs. SGLN.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF | 4.86% | 23.81% | -0.32% | 0.33% | -1.55% | 0.90% | 23.11% | 21.63% | -6.34% | -3.31% |
SGLN.L iShares Physical Gold ETC | 3.89% | 53.66% | 28.20% | 7.24% | 11.84% | -2.57% | 19.62% | 14.63% | 4.36% | -1.33% |
Correlation
The correlation between BTEK.L and SGLN.L is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Oct 25, 2017 | 0.07 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BTEK.L vs. SGLN.L — Risk / Return Rank
BTEK.L
SGLN.L
BTEK.L vs. SGLN.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) and iShares Physical Gold ETC (SGLN.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BTEK.L | SGLN.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.79 | ||
| Sortino ratioReturn per unit of downside risk | +1.25 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.29 | +0.09 |
| Calmar ratioReturn relative to maximum drawdown | 6.23 | 1.91 | +4.32 |
| Martin ratioReturn relative to average drawdown | 17.55 | 5.05 | +12.51 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BTEK.L | SGLN.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.24 | 1.45 | +0.79 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.29 | 1.23 | -0.94 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.90 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.31 | 0.55 | -0.24 |
Drawdowns
BTEK.L vs. SGLN.L - Drawdown Comparison
The maximum BTEK.L drawdown since its inception was -30.86%, smaller than the maximum SGLN.L drawdown of -41.71%. Use the drawdown chart below to compare losses from any high point for BTEK.L and SGLN.L.
Loading charts...
Drawdown Indicators
| BTEK.L | SGLN.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -30.86% | -41.71% | +10.85% |
Max Drawdown (1Y)Largest decline over 1 year | -6.89% | -17.57% | +10.68% |
Max Drawdown (3Y)Largest decline over 3 years | -26.34% | -17.57% | -8.77% |
Max Drawdown (5Y)Largest decline over 5 years | -30.86% | -17.57% | -13.29% |
Max Drawdown (10Y)Largest decline over 10 years | — | -21.91% | — |
Current DrawdownCurrent decline from peak | -1.86% | -16.01% | +14.15% |
Average DrawdownAverage peak-to-trough decline | -10.04% | -14.76% | +4.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.45% | 6.67% | -4.22% |
Volatility
BTEK.L vs. SGLN.L - Volatility Comparison
iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) has a higher volatility of 6.91% compared to iShares Physical Gold ETC (SGLN.L) at 5.08%. This indicates that BTEK.L's price experiences larger fluctuations and is considered to be riskier than SGLN.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BTEK.L | SGLN.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.91% | 5.08% | +1.83% |
Volatility (6M)Calculated over the trailing 6-month period | 14.67% | 20.08% | -5.41% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.14% | 23.19% | -4.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.08% | 16.30% | +3.78% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 21.71% | 15.78% | +5.93% |
BTEK.L vs. SGLN.L - Expense Ratio Comparison
BTEK.L has a 0.35% expense ratio, which is higher than SGLN.L's 0.12% expense ratio.
Dividends
BTEK.L vs. SGLN.L - Dividend Comparison
Neither BTEK.L nor SGLN.L has paid dividends to shareholders.
Frequently Asked Questions
BTEK.L and SGLN.L have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, SGLN.L is cheaper at 0.12% per year. The better choice depends on whether you care most about return, fees, risk, or income.
SGLN.L is cheaper with a 0.12% expense ratio, compared with 0.35% for BTEK.L.
BTEK.L is categorized as Health & Biotech Equities, while SGLN.L is Gold. BTEK.L tracks NASDAQ Biotechnology TR USD, while SGLN.L tracks LBMA Gold Price. Their fees differ too: 0.35% for BTEK.L and 0.12% for SGLN.L.
Find the right allocation for BTEK.L and SGLN.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer